When does Abbott report and what are the expectations?

Abbott Labs (ABT) reports Q1 2026 earnings before the market opens on Thursday, April 16, 2026. Analysts expect EPS of $1.15 and revenue of approximately $10.99 billion. Abbott is one of the largest diversified healthcare companies globally, with segments spanning medical devices, diagnostics, nutrition, and established pharmaceuticals.

What should investors watch in Abbott's Q1 report?

Three things: (1) FreeStyle Libre CGM (continuous glucose monitor) growth — Abbott's diabetes care device is a global category leader and a key growth driver. (2) Diagnostics revenue recovery post-COVID — rapid test demand has normalized, but core lab testing should show steady growth. (3) Any tariff or supply chain commentary — medical device manufacturers are exposed to the US-China trade friction and materials costs.

How has Abbott's stock been performing?

Abbott is a defensive healthcare name with relatively low beta. The stock has held up better than cyclical sectors during the Iran war volatility. It's in the watchlist with a current VST score of 1.15 (HOLD) and a combined signal score of ~0.47-0.52 depending on GDELT readings. A strong beat could push it toward BUY territory.

What is the macro context for Abbott's report?

Healthcare is seeing mixed forces: defensive bid from Iran war uncertainty (positive), potential tariff headwinds on imported medical components (negative), and strong underlying demand for diabetes devices as GLP-1 drugs shift the treatment paradigm toward monitoring rather than insulin. Abbott's CGM franchise may benefit from the GLP-1 wave as more patients monitor metabolic health.

What other companies report this week after Abbott?

Netflix (NFLX) reports AMC tonight (April 15) — results may be available by Thursday morning. United Airlines (UAL) reports April 21 AMC. The earnings season has been broadly strong: JPM, WFC, BAC, GS, C, BLK, and ASML all beat estimates in the past week.

Earnings Preview: Abbott Labs (ABT) — Q1 2026

Reports Thursday, April 16, 2026 — Before Market Open

The Setup

Metric	Consensus Estimate
EPS	$1.15
Revenue	~$10.99B
Report Time	BMO Thursday
Prior Q1 2025 EPS	~$0.98

What to Watch

1. FreeStyle Libre (CGM) Revenue
Abbott’s diabetes monitoring franchise is the crown jewel. FreeStyle Libre is #1 globally in continuous glucose monitoring. Watch for: international expansion metrics, competition from Dexcom G7, and any benefit from the GLP-1 drug adoption wave driving broader metabolic health awareness.

2. Diagnostics Recovery Trajectory
Post-pandemic rapid test volumes have normalized. The question is whether core lab diagnostic growth is offsetting the COVID windfall decline. Organic growth in the mid-single digits would be in line with expectations.

3. Medical Devices Margin
Structural heart, electrophysiology, and neuromodulation device revenues should show steady growth. Watch for any tariff or supply chain commentary — medical device components have some China exposure.

4. Full-Year Guidance Tone
Does management raise, maintain, or lower FY2026 guidance? Given the Iran uncertainty in Q1, any positive guidance revision would be notable.

Signal Implications

Scenario	CS Impact
Beat + Raised guidance	UNH/healthcare sector boost; UNH might clear HOLD boundary
In-line	Neutral; no signal change
Miss or guided lower	Healthcare sector drag; UNH stays SELL

Abbott is not in Ray’s core watchlist (GOOGL, AMD, AMZN, CVX, UNH, PLTR, LMT, DAL) but its results set the tone for UNH and the broader healthcare trade.

Ray’s signal engine · signals.themenonlab.com

Earnings Preview: Abbott Labs (ABT) Reports Q1 2026 Thursday Morning

Earnings Preview: Abbott Labs (ABT) — Q1 2026

The Setup

What to Watch

Signal Implications